Skip to Content
Merck
CN
  • Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation.

Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation.

Journal of controlled release : official journal of the Controlled Release Society (2020-03-23)
Caroline Tsao, Zhefan Yuan, Peng Zhang, Erik Liu, Patrick McMullen, Kan Wu, Hsiang-Chieh Hung, Shaoyi Jiang
ABSTRACT

Pulmonary delivery of protein drugs into the systemic circulation is highly desirable as the lung provides a large absorption surface area and a more favorable environment for biologics compared to other delivery routes. However, pulmonary systemic delivery of proteins presents several challenges such as poor protein stability and limited bioavailability, especially for large proteins (molecular weight > 50 kDa), which exhibit an average bioavailability of 1% to 5% when delivered via the pulmonary route. Here, we demonstrated that with the conjugation of zwitterionic poly(carboxybetaine) (pCB) polymer, the bioavailability of organophosphate hydrolase (OPH) was significantly increased from 5% to 53%. OPH conjugated with pCB delivered through intubation-assisted intratracheal instillation (IAIS) into the lung exhibited improved pharmacokinetic properties and prophylactic efficacy against organophosphate poisoning, showing its application potential. Zwitterionic polymer conjugation provides the possibility for a favorable, non-invasive delivery of biological therapeutics into the systemic circulation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-Hydroxysulfosuccinimide sodium salt, ≥98% (HPLC)
Sigma-Aldrich
2-Iminothiolane hydrochloride, ≥98% (TLC), powder